The shares are listed on the Nasdaq Global Select Market

Davis Polk advised as sales agent in connection with the SEC-registered at-the-market offering by NGM Biopharmaceuticals, Inc. of its common stock for up to an aggregate amount of $100 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “NGM.”

Based in South San Francisco, California, NGM is a biopharmaceutical company focused on discovering and developing novel, potentially life-changing medicines based on scientific understanding of key biological pathways underlying grievous diseases with critical unmet or underserved patient need.

The Davis Polk corporate team included partner Stephen Salmon and associates Dana Lueck-Mammen, Michael Kostukovsky (on leave), Sunny Xu and Savannah J. Dowling. The intellectual property team included partner David R. Bauer and associate Jordan Khorshad. Members of the Davis Polk team are based in the Northern California and New York offices.